[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitality\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitality":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100645084","evaluation-of-applex-apple-extract-on-anti-inflammatory-and-healthy-aging-effects-100645084",false,"NCT07678346","Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects","A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Anti-Inflammatory and Healthy Aging Effects of AppleX™ Apple Extract (15% Fisetin) in Adults 45-70 Years of Age","Inclusion Criteria:\n\n* Age 45-70 years at time of enrollment\n* Meets questionnaire-based inflammatory enrichment criteria (at least 2 of 5 risk factors, per Section 4.2)\n* Non-smoker (no tobacco or nicotine use within 6 months of enrollment)\n* Willing and able to maintain stable diet, exercise habits, and supplement use throughout the 24-week study period\n* No major medication changes planned during the study period\n* Willing to perform home-based DBS collections at T0, T12, and T24\n* Access to a smartphone or computer to complete eConsent and online questionnaires\n* Able to provide informed consent via the Alethios eConsent platform\n\nExclusion Criteria:\n\n* Current use of prescription anti-inflammatory medications including NSAIDs (regular use ≥3x\u002Fweek), corticosteroids, or DMARDs\n* Diagnosis of an autoimmune or inflammatory disease (e.g., rheumatoid arthritis, lupus, IBD, multiple sclerosis)\n* Active or unstable cardiovascular disease requiring medication changes during the study period\n* History of cancer within the past 5 years (except non-melanoma skin cancer)\n* Regular use of supplemental fisetin, quercetin, or resveratrol within 30 days of enrollment\n* Pregnancy, breastfeeding, or planning to become pregnant during the study\n* Known allergy to apple or apple-derived products\n* Body mass index (BMI) \\>40 kg\u002Fm²",true,"ALL","45 Years","70 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if AppleX™ Apple Extract can help lower systemic inflammation in adults aged 45-70 with signs of low-grade inflammation. It will also look at the extract's effects on fatigue, joint comfort, and biological aging metrics.\n\nThe main questions it aims to answer are:\n\n* Does taking AppleX™ Apple Extract daily lower high-sensitivity C-reactive protein (hsCRP) levels, a key marker of inflammation in the blood?\n* Does AppleX™ Apple Extract improve participant-reported fatigue and joint comfort?\n* Does the extract slow down biological or epigenetic aging metrics compared to a placebo?\n\nResearchers will compare AppleX™ Apple Extract to a placebo (a look-alike capsule that contains no active ingredients) to see if the apple extract has a measurable anti-inflammatory and healthy aging effect.",[28,29,30,31],"Systemic Inflammation (hsCRP)","Healthy Aging","Vitality","Healthy Adult Participants",[33,34,35,36],"Apple extract","Fisetin","Flavonoids","polyphenols","NOT_YET_RECRUITING","2026-06-25",{"date":40,"type":41},"2026-07-01","ACTUAL",{"date":43,"type":22},"2026-07",{"date":45,"type":22},"2027-02",{"name":47,"class":48},"Nutraland USA, Inc.","INDUSTRY",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":79,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100590537","project-icope-brazil-assessment-of-intrinsic-capacity-in-brazilian-older-adults-100590537","NCT06968702","Project ICOPE Brazil: Assessment of Intrinsic Capacity in Brazilian Older Adults","Project ICOPE Brazil: Assessment of Intrinsic Capacity in Older Adults as a Basis for Implementation of the WHO ICOPE Strategy in the Unified Health System.","ICOPE-BR","Inclusion Criteria:\n\n* People aged ≥ 60 years, with no age limit;\n* Being registered (with available contact information) in the participating health care units;\n* Being available to go in person to the data collection sites for the assessments.\n\nExclusion criteria\n\n* Inability to access the data collection site;\n* Severe neurologic and\u002For cognitive impairments that preclude interaction with the evaluators to complete the proposed tests and data collections;\n* Advanced serious illness or under palliative care:\n\nClinical Frailty Scale (CFS)20 score of 8 (severely frail) or 9 (terminally ill).","60 Years",{"count":60,"type":22},3838,"OBSERVATIONAL","The ICOPE Brazil study aims to understand aging trajectories in Brazil, especially healthy aging trends based on intrinsic capacity, a collective of mental and physical capacities one may have to maintain their functional ability to execute daily life activities. Tests and questionnaires will be applied to collect data on mobility capacity, cognitive capacity, nutritional status, vision, and hearing (sensorial) capacities, and mental health. These assessments are in consonance with what the World Health Organization proposed in the Integrated Care for Older People Program (ICOPE). Participants will be followed up for three years, and the primary outcomes of interest are loss of intrinsic capacity, mobility impairment, cognitive impairment, incident depressive symptoms, loss of functional ability, incident frailty, incident sarcopenia, incident falls, hospitalization, multimorbidity, and mortality.",[64,65,66,29,67,68,69,70,71,72,73,74,75,76,30,77,78],"Intrinsic Capacity","Frailty","Aging","Functional Ability","Mobility and Independence","Cognitive Ability, General","Cognitive Impairment","Sensory Hearing Loss","Sensory Deficits","Visual Acuity","Visual Impairment","Mood Disorders","Depressive Symptoms","Nutritional Risk","Nutrition Assessment",[80,67,81,82,83,65,70,84,85,30,86,87,88,89],"Instrinsic Capacity","ICOPE","Aging trends","Older Adults","Mobility","Sensory","Psychological","Cohort","healthy aging","public health","2025-05-05",{"date":92,"type":41},"2025-05-13",{"date":94,"type":22},"2025-05-15",{"date":96,"type":22},"2029-11",{"name":98,"class":99},"University of Sao Paulo","OTHER"]